shMUC1-B16F10 cell vaccine

**shMUC1-B16F10 cell vaccine** is a whole-tumor lysate cellular vaccine derived from murine B16F10 melanoma cells in which the Mucin 1 (MUC1) gene has been silenced by short hairpin RNA (shRNA)[1]. The silencing is achieved by lentiviral vector-mediated transfection, resulting in decreased MUC1 expression and altered cell cycle and proliferation[1]. The vaccine is prepared by repeated freeze-thawing of the shMUC1-B16F10 cells, yielding lysate that is subcutaneously administered to mice. The primary aim is immunization against melanoma, with investigation into the role of MUC1 as a tumor antigen. The mechanism involves the induction of anti-tumor immunity through presentation of tumor-associated antigens from the cell lysate. The vaccine modulates the immune response by affecting natural killer cell cytotoxicity, and production of key immunological factors (IFN-γ, anti-MUC1 antibodies, perforin, granzyme B), but the silencing of MUC1 reduces overall immunogenicity and anti-tumor efficacy compared to standard B16F10 cell vaccines[1].

Other names

shMUC1-B16F10 melanoma vaccineshMUC-1-B16F10 melanoma vaccineshMUC 1-B16F10 melanoma vaccineMUC1-silenced B16F10 cell vaccineMUC-1-silenced B16F10 cell vaccineMUC 1-silenced B16F10 cell vaccine